The COVID-19 vaccine Covaxin, which was approved for emergency use in India ahead of late-stage trial results, may be coming to the U.S., as its manufacturer, Bharat Biotech, has secured a U.S. partner and plans to seek Emergency Use Authorization (EUA) from the FDA for distribution in the U.S.